Lyell Immunopharma, Inc. · NASDAQ:LYEL
Lyell Immunopharma, Inc. shareholders
As of Sep 30, 2026, 99 institutions reported holding Lyell Immunopharma, Inc., 49.2% of its shares. Largest: ARCH Venture Management, LLC, GSK plc and Vanguard. New holders, exits, insiders and big stakes, each with its filing.
| Holder | Shares | % of Lyell Immunopharma, Inc. | Change | Filed |
|---|---|---|---|---|
| ARCH Venture Management, LLC | 3.25M | 13.2% | no change | Nov 16, 2026 |
| GSK plc | 1.51M | 6.2% | no change | Nov 5, 2026 |
| Vanguard | 916K | 3.7% | −60,466 | Nov 13, 2026 |
| BlackRock | 799K | 3.3% | +74,715 | Nov 13, 2026 |
| Orland Properties Ltd | 755K | 3.1% | no change | Nov 13, 2026 |
| Almitas Capital LLC | 448K | 1.8% | −133K | Nov 16, 2026 |
| AQR Capital Management LLC | 346K | 1.4% | new | Nov 16, 2026 |
| venBio Partners LLC | 338K | 1.4% | no change | Nov 16, 2026 |
| Alphabet Inc. | 293K | 1.2% | no change | Nov 5, 2026 |
| Opaleye Management Inc. | 291K | 1.2% | −52,672 | Nov 16, 2026 |